ASX - By Stock
|
CHM |
Re:
Ann: First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
|
|
KrushingIt
|
35 |
7.4K |
1 |
09:22 |
09:22 |
ASX - By Stock
|
35
|
7.4K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
|
|
KrushingIt
|
35 |
7.4K |
6 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
35
|
7.4K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Ann: First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
|
|
KrushingIt
|
35 |
7.4K |
3 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
35
|
7.4K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
|
|
KrushingIt
|
35 |
7.4K |
3 |
23/07/24 |
23/07/24 |
ASX - By Stock
|
35
|
7.4K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
|
|
KrushingIt
|
35 |
7.4K |
8 |
22/07/24 |
22/07/24 |
ASX - By Stock
|
35
|
7.4K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
CDH17 Car T therapy has blockbuster potential
|
|
KrushingIt
|
8 |
2.7K |
1 |
22/07/24 |
22/07/24 |
ASX - By Stock
|
8
|
2.7K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
|
|
KrushingIt
|
35 |
7.4K |
4 |
22/07/24 |
22/07/24 |
ASX - By Stock
|
35
|
7.4K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
|
|
KrushingIt
|
35 |
7.4K |
10 |
22/07/24 |
22/07/24 |
ASX - By Stock
|
35
|
7.4K
|
10
|
|
ASX - By Stock
|
CHM |
Re:
CDH17 Car T therapy has blockbuster potential
|
|
KrushingIt
|
8 |
2.7K |
11 |
20/07/24 |
20/07/24 |
ASX - By Stock
|
8
|
2.7K
|
11
|
|
ASX - By Stock
|
CHM |
Re:
CDH17 Car T therapy has blockbuster potential
|
|
KrushingIt
|
8 |
2.7K |
8 |
19/07/24 |
19/07/24 |
ASX - By Stock
|
8
|
2.7K
|
8
|
|
ASX - By Stock
|
CHM |
CDH17 Car T therapy has blockbuster potential
|
|
KrushingIt
|
8 |
2.7K |
19 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
8
|
2.7K
|
19
|
|
ASX - By Stock
|
TVN |
Re:
Tivan - news and media
|
|
KrushingIt
|
225 |
83K |
12 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
225
|
83K
|
12
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
772 |
309K |
2 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
772
|
309K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
772 |
309K |
3 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
772
|
309K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
772 |
309K |
2 |
07/07/24 |
07/07/24 |
ASX - By Stock
|
772
|
309K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
772 |
309K |
12 |
05/07/24 |
05/07/24 |
ASX - By Stock
|
772
|
309K
|
12
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
KrushingIt
|
284 |
77K |
8 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
284
|
77K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Webinar 17/06/24
|
|
KrushingIt
|
25 |
6.9K |
5 |
18/06/24 |
18/06/24 |
ASX - By Stock
|
25
|
6.9K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
KrushingIt
|
284 |
77K |
7 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
284
|
77K
|
7
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
KrushingIt
|
284 |
77K |
3 |
27/05/24 |
27/05/24 |
ASX - By Stock
|
284
|
77K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CDH17 Phase 1/2 clinical trial approved for initiation
|
|
KrushingIt
|
18 |
7.0K |
26 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
18
|
7.0K
|
26
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Resignation of CEO and Managing Director
|
|
KrushingIt
|
61 |
22K |
2 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
61
|
22K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Chimeric opens CHM CDH17 Phase 1/2 trial
|
|
KrushingIt
|
14 |
3.7K |
5 |
22/05/24 |
22/05/24 |
ASX - By Stock
|
14
|
3.7K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CDH17 Phase 1/2 clinical trial approved for initiation
|
|
KrushingIt
|
18 |
7.0K |
8 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
18
|
7.0K
|
8
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
772 |
309K |
4 |
19/05/24 |
19/05/24 |
ASX - By Stock
|
772
|
309K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment
|
|
KrushingIt
|
17 |
4.3K |
12 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
17
|
4.3K
|
12
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment
|
|
KrushingIt
|
17 |
4.3K |
11 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
17
|
4.3K
|
11
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM CORE-NK vactosertib Phase 1b study re-opens enrolment
|
|
KrushingIt
|
17 |
4.3K |
5 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
17
|
4.3K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
KrushingIt
|
284 |
77K |
1 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
284
|
77K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Resignation of CEO and Managing Director
|
|
KrushingIt
|
61 |
22K |
4 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
61
|
22K
|
4
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Resignation of CEO and Managing Director
|
|
KrushingIt
|
61 |
22K |
5 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
61
|
22K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
772 |
309K |
9 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
772
|
309K
|
9
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
772 |
309K |
9 |
29/04/24 |
29/04/24 |
ASX - By Stock
|
772
|
309K
|
9
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
772 |
309K |
16 |
26/04/24 |
26/04/24 |
ASX - By Stock
|
772
|
309K
|
16
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
772 |
309K |
9 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
772
|
309K
|
9
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
772 |
309K |
7 |
25/04/24 |
25/04/24 |
ASX - By Stock
|
772
|
309K
|
7
|
|
ASX - By Stock
|
TVN |
Re:
Ann: Tivan Upgrades Resource Estimate - Speewah Flourite Project
|
|
KrushingIt
|
32 |
13K |
28 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
32
|
13K
|
28
|
|
ASX - By Stock
|
CHM |
Re:
Chimeric: Media Thread
|
|
KrushingIt
|
772 |
309K |
7 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
772
|
309K
|
7
|
|
ASX - By Stock
|
TVN |
Re:
MASDP Public Hearings in NT
|
|
KrushingIt
|
26 |
10K |
18 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
26
|
10K
|
18
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Change of Director's Interest Notice PH
|
|
KrushingIt
|
2 |
1.4K |
3 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
2
|
1.4K
|
3
|
|